We are initiating coverage on Tenax Therapeutics (TENX) with a Buy rating and a first price target of $25 based on discounted cash flow, DCF valuation. Phase 3 data for the company's asset TNX-103, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results